Help to generate the slides. Emphasize key comparative efficacy messages that highlight FRUZAQLAâ€™s balanced efficacy profile relative to existing late-line therapies. Include study design details from the FRESCO study and relevant adverse reactions along with the primary endpoint of the FRESO trial. The slides should engage clinicians who prioritize impactful treatment options by focusing on FRUZAQLA as an effective, highly tolerable choice with a more balanced profile than competitors.